Links to Helpful Studies and HES Updates

Long-term Clinical Outcomes of High Dose Mepolizumab Treatment for Hypereosinophilic Syndrome
May, 2018 - The Journal of Allergy and Clinical Immunology: In Practice
GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US
December, 2017 - GlaxoSmithKline Pharmaceuticals
FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome
December, 2017 - FDA
Clinical and Biological Markers in Hypereosinophilic Syndromes
December, 2017 - U.S. National Library of Medicine, National Institutes of Health
Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
March, 2008 - U.S. National Library of Medicine, National Institutes of Health
This site was designed with the
.com
website builder. Create your website today.
Start Now